Context: Mouse studies suggest that adropin, a peptide hormone, is required for metabolic homeostasis and prevention of obesity-associated insulin resistance. Whether obesity and insulin resistance are associated with low plasma adropin levels in humans is not known. Objectives: Our objective was to investigate the hypothesis that obesity and indicators of insulin resistance are associated with low adropin levels and determine whether weight loss regulates adropin levels. Design and Participants: Plasma was obtained from 85 female [age 21-67 yr, body mass index (BMI) 19.4-71.5 kg/m2] and 45 male (age 18-70 yr, BMI 19.1-62.6 kg/m2) volunteers for other clinical studies. The impact of Roux-en-Y gastric bypass was investigated in 19 obese females (BMI 37-65 kg/m2) using samples collected at baseline and 1-12 months after surgery. Results: Adropin levels correlate negatively with BMI (r = -0.335, P < 0.001) and age (r = -0.263, P = 0.003). Age-adjusted adropin levels are higher in males [4.1 ng/ml; 95% confidence interval (CI) = 3.6-4.6 ng/ml] than females (3.0 ng/ml; 95% CI = 2.6 -3.4 ng/ml) (P = 0.001). In all subjects, lower age-adjusted adropin levels were observed in overweight (3.3 ng/ml; 95% CI = 2.8 -3.8 ng/ml, P = 0.033) and obese (2.7 ng/ml; 95% CI = 2.1-3.3 ng/ml, P = 0.001) compared with healthy-weight subjects (4.1 ng/ml; 95% CI = 3.6-4.5 ng/ml). This effect was gender specific (weight category x gender, P < 0.001) and was observed in males only. Aging and diagnosis with two or more metabolic syndrome risk factors was associated with low adropin levels, irrespective of sex. Adropin concentrations increased after Roux-en-Y gastric bypass, peaking 3 months after surgery (P < 0.01). Conclusions: Although males exhibit higher adropin levels that are reduced by obesity, aging and markers of insulin resistance are associated with low plasma adropin irrespective of sex.
ASJC Scopus subject areas
- Clinical Biochemistry
- Biochemistry, medical
- Endocrinology, Diabetes and Metabolism